Knoll Capital Management’s Cardiol Therapeutics CRDL Stock Holding History

Knoll Capital Management’s Portfolio CRDL Stock Details CRDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$135K	Hold	100,000	–	–	0.07%	34
2025 Q4	$95.3K	Hold	100,000	–	–	0.04%	32
2025 Q3	$107K	Hold	100,000	–	–	0.06%	37
2025 Q2	$136K	Hold	100,000	–	–	0.1%	37
2025 Q1	$96.9K	Hold	100,000	–	–	0.06%	36
2024 Q4	$128K	Hold	100,000	–	–	0.08%	32
2024 Q3	$198K	Hold	100,000	–	–	0.09%	34
2024 Q2	$202K	Buy	+100,000	New	+$212K	0.14%	34

Other funds holding CRDL

MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return

Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Knoll Capital Management's CRDL Position: Q1 2026 in Review

Knoll Capital Management held its Cardiol Therapeutics (CRDL) position steady in Q1 2026 at 100,000 shares worth $135K. The position accounts for 0.07% of the portfolio, ranked #34.

Knoll Capital Management first reported a position in CRDL in Q2 2024 and has held it in 8 quarters since. The position peaked at $202K in Q2 2024. 47 funds tracked by Wall St. Rank hold CRDL as of Q1 2026.

Knoll Capital Management held 100,000 shares of Cardiol Therapeutics worth $135K as of Q1 2026.
Knoll Capital Management left its Cardiol Therapeutics share count unchanged in Q1 2026.
Cardiol Therapeutics made up 0.07% of Knoll Capital Management's portfolio in Q1 2026, its #34 holding.
Knoll Capital Management first reported a position in Cardiol Therapeutics in Q2 2024 and has held it in 8 quarters since.
Knoll Capital Management's Cardiol Therapeutics position peaked at $202K in Q2 2024.
47 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q1 2026.

Based on Knoll Capital Management's 13F filing for Q1 2026, filed 15 May 2026.